Zacks Investment Research downgraded Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to Sell in a report released today.
- Updated: January 11, 2017
Yesterday Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) traded -3.17% lower at $15.86. The company’s 50-day moving average is $15.59 and its 200-day moving average is $14.43. The last closing price is up 9.88% from the 200-day moving average, compared to the S&P 500 which has decreased -0.04% over the same time. 1,203,525 shares of the stock were exchanged, down from an average trading volume of 1,352,240
Zacks Investment Research has downgraded Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to Sell in a report released on 1/11/2017.
Previously on 12/11/2015, BTIG Research reported on Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) raised the target price from $0.00 to $15.00. At the time, this indicated a possible upside of 0.38%.
See Chart Below
Ironwood Pharmaceuticals, Inc. has a 52 week low of $7.35 and a 52 week high of $16.89 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 12 brokers have issued a report on the stock. The consensus target price is $12.42 with 2 brokers rating the stock a strong buy, 3 brokers rating the stock a buy, 6 brokers rating the stock a hold, 1 broker rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company's products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. It operates through human therapeutics segment. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. It is engaged in developing therapeutic platforms for the treatment of vascular and fibrotic diseases, and refractory gastroesophageal reflux disease (GERD). Its IW-9179 is used for the treatment of gastroparesis and functional dyspepsia. The Company has conducted an exploratory Phase IIa clinical study of IW-3718 in patients with refractory GERD. It has two sGC development candidates, which include IW-1973 and IW-1701.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.